Newer gen azoles of itraconazole is not working
Reading File
Researching newer-generation azoles after itraconazole and why they may fail in clinical practice.
search_medical_text
newer generation azoles after itraconazole voriconazole posaconazole isavuconazole spectrum activity
Management of Candidiasis
Page 11
search_medical_text
azole antifungal resistance mechanisms failure clinical
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 6277
GradeResponse
GradeResponse
Here is a comprehensive breakdown of the newer-generation azoles (post-itraconazole) and the reasons they may fail:
Newer-Generation Azoles After Itraconazole
The triazole antifungals that came after itraconazole are:
| Drug | Generation | Key Advance over Itraconazole |
|---|---|---|
| Voriconazole | 2nd gen | Broader mold coverage (esp. Aspergillus), better CNS penetration |
| Posaconazole | 2nd gen | Extended spectrum including mucormycetes (prophylaxis) |
| Isavuconazole | 3rd gen (expanded-spectrum) | Active against mucormycetes + Aspergillus; better tolerability, fewer drug interactions |
All work via the same mechanism: inhibition of lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis.
Why Newer Azoles May Fail
1. Intrinsic Resistance (Species-Level)
- Candida krusei — intrinsically resistant to fluconazole and has reduced susceptibility to voriconazole
- Candida glabrata — reduced susceptibility across the azole class (all generations)
- Mucor/Rhizopus species — NOT covered by voriconazole (a key clinical trap); require posaconazole or isavuconazole
2. Acquired/Induced Resistance (Mechanisms)
| Mechanism | Detail |
|---|---|
| ERG11 (CYP51) mutations | Point mutations in the target enzyme reduce drug binding affinity |
| Efflux pump upregulation | CDR1/CDR2 (ATP-binding cassette) and MDR1 (major facilitator superfamily) pumps actively expel the drug |
| ERG3 mutations | Bypass the need for ergosterol, rendering the drug irrelevant |
| Environmental azole exposure | Aspergillus fumigatus resistance increasingly driven by agricultural azole fungicide use (TR34/L98H mutation in ERG11) — found globally even in azole-naive patients |
Per Harrison's (p. 6277): "Resistance in A. fumigatus to one or more azoles, although uncommon, is increasingly found globally... resistance arising from multiple mechanisms may develop during long-term treatment, and a positive culture during antifungal therapy is an indication for susceptibility testing."
3. Pharmacokinetic/Pharmacodynamic Failures
- Voriconazole: Highly variable plasma levels due to CYP2C19 polymorphism (poor vs. ultra-rapid metabolizers); therapeutic drug monitoring (TDM) is essential (target trough: 1–5.5 mg/L)
- Posaconazole (oral suspension): Requires fatty food and acidic pH for absorption — unreliable in patients with mucositis, diarrhea, or PPI use; delayed-release tablet/IV formulations overcome this
- Itraconazole: Similar absorption issues; capsule requires acid, solution is better but poorly tolerated
- All azoles are fungistatic (not fungicidal) against most fungi — immunocompromised patients may not clear infection even with adequate levels
4. Drug-Drug Interactions
All azoles inhibit CYP450 enzymes to varying degrees (per Management of Candidiasis, p. 11), leading to:
- Increased levels of calcineurin inhibitors (tacrolimus, cyclosporine), sirolimus, certain chemotherapeutics
- Competitive metabolism altering antifungal levels (e.g., rifampicin markedly reduces azole levels)
5. Wrong Drug for the Fungus
- Voriconazole has a "mold gap" — it does not cover mucormycetes; using it empirically in suspected mucormycosis is a critical clinical error
- Isavuconazole covers both Aspergillus and mucormycetes, filling this gap
Clinical Bottom Line
If a newer azole is not working, consider:
- Send susceptibility testing — especially in Aspergillus (TR34/L98H resistance, environmental source)
- Check drug levels (TDM) — especially voriconazole
- Reassess the organism — is it a species/mold not covered by the chosen azole?
- Assess host factors — immunosuppression severity, abscess/biofilm (azoles penetrate biofilm poorly)
- Switch class — echinocandins (Candida biofilm/glabrata) or liposomal amphotericin B (mucormycetes, azole-resistant molds)
This is a shared conversation. Sign in to Orris to start your own chat.